190 related articles for article (PubMed ID: 38515651)
1. Anlotinib plus tislelizumab for recurrent metastatic pancreas ductal adenocarcinoma with germline BRCA2 mutation: A case report.
Peng S; Huang H; Zhu X; Chen J; Ding X; Wang F; Chen L; Lu Z
Exp Ther Med; 2024 May; 27(5):178. PubMed ID: 38515651
[TBL] [Abstract][Full Text] [Related]
2. Case Report: Pulmonary sarcomatoid carcinoma complicating TP53 mutation treated successfully with Tislelizumab combined with Anlotinib-a case report.
Li YF; Zhao XF; Tian Y; Xiao XY; Yan CY; Shen H
Front Genet; 2022; 13():949989. PubMed ID: 35938033
[TBL] [Abstract][Full Text] [Related]
3. Case Report: PD-L1-negative advanced bladder cancer effectively treated with anlotinib and tislelizumab: A report of two cases.
Li T; Hu W; Jin L; Yin X; Kang D; Piao L
Front Oncol; 2023; 13():1164368. PubMed ID: 37124509
[TBL] [Abstract][Full Text] [Related]
4. Late-stage esophageal neuroendocrine carcinoma in a patient treated with tislelizumab combined with anlotinib: a case report.
Zhang Y; Liu X; Liang H; Liu W; Wang H; Li T
J Int Med Res; 2023 Jul; 51(7):3000605231187942. PubMed ID: 37498227
[TBL] [Abstract][Full Text] [Related]
5. Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report.
Shimmura H; Kuramochi H; Jibiki N; Katagiri S; Nishino T; Araida T
Jpn J Clin Oncol; 2019 Dec; 49(11):1049-1054. PubMed ID: 31612916
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Metastatic Primary Extramammary Paget Disease With Combination Anlotinib and Tislelizumab: A Case Report and Review of the Literature.
Yin X; Li X; Li M; She Q; Liu Y; Chen X; Ma S; Ma Q; Huang Z; Xu L; Huang X; Zhan Z; Che X
Front Med (Lausanne); 2022; 9():891958. PubMed ID: 35685408
[TBL] [Abstract][Full Text] [Related]
7. Case Report: Anlotinib combined with PD-1 inhibitor and sequential GA regimen or FOLFIRINOX Chemotherapy in treatment of KRAS G12V mutated pancreatic ductal adenocarcinoma with liver metastasis: A case and literature review.
Wang Y; Wang B; Xiang L; Deng J; Xu B; He P; Pu W; Wang H; Fan Y; Chen H
Front Immunol; 2022; 13():1016647. PubMed ID: 36311715
[TBL] [Abstract][Full Text] [Related]
8. Response to olaparib in metastatic lung adenocarcinoma with germline BRCA2 mutation: a case report.
Wu C; Fan M; Hu Y
Anticancer Drugs; 2022 Jan; 33(1):e734-e737. PubMed ID: 34387603
[TBL] [Abstract][Full Text] [Related]
9. Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma: a retrospective cohort.
Wu H; Huang N; Zhao C; Hu X; Da L; Huang W; Shen Y; Xiong F; Zhang C
Ann Transl Med; 2022 Mar; 10(6):294. PubMed ID: 35433955
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of Brca2 cooperates with Trp53(R172H) to induce invasive pancreatic ductal adenocarcinomas in mice: a mouse model of familial pancreatic cancer.
Feldmann G; Karikari C; dal Molin M; Duringer S; Volkmann P; Bartsch DK; Bisht S; Koorstra JB; Brossart P; Maitra A; Fendrich V
Cancer Biol Ther; 2011 Jun; 11(11):959-68. PubMed ID: 21455033
[TBL] [Abstract][Full Text] [Related]
11. Excellent Response to Olaparib in a Patient with Metastatic Pancreatic Adenocarcinoma with Germline
Pimenta JR; Ueda SKN; Peixoto RD
Case Rep Oncol; 2020; 13(2):904-910. PubMed ID: 32884538
[TBL] [Abstract][Full Text] [Related]
12. Case report: Significant benefits of tislelizumab combined with anlotinib in first-line treatment of metastatic renal pelvic urothelial carcinoma with sarcomatoid carcinoma differentiation.
Zhu S; Yu C; Wang C; Ding G; Cheng S
Front Oncol; 2022; 12():969106. PubMed ID: 36330483
[TBL] [Abstract][Full Text] [Related]
13. Complete Response to Chemotherapy in Metastatic Pancreatic Carcinoma Associated with Double Heterozygous Germline Mutation in BRCA2 and CHEK2 Genes - a Case Report.
Pazderová N; Urbán V; Makovník M; Macák D; Janega P; Chovanec M; Rejleková K; Mardiak J; Mego M
Klin Onkol; 2020; 33(3):220-225. PubMed ID: 32683879
[TBL] [Abstract][Full Text] [Related]
14. BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma.
Blair AB; Groot VP; Gemenetzis G; Wei J; Cameron JL; Weiss MJ; Goggins M; Wolfgang CL; Yu J; He J
J Am Coll Surg; 2018 Apr; 226(4):630-637.e1. PubMed ID: 29309945
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non-Small-Cell Lung Cancer After Previous Systemic Treatment Failure-A Retrospective Study.
Wang P; Fang X; Yin T; Tian H; Yu J; Teng F
Front Oncol; 2021; 11():628124. PubMed ID: 33791214
[TBL] [Abstract][Full Text] [Related]
16. Case report of penile squamous cell carcinoma continuous treatment with BRCA2 mutation.
Zhang Q; Li Y; Zhang Y; Deng Z; Ding Y
World J Surg Oncol; 2024 Feb; 22(1):50. PubMed ID: 38336701
[TBL] [Abstract][Full Text] [Related]
17. A case report: A new promising treatment for pulmonary sarcomatoid carcinoma - Tislelizumab and Anlotinib combined with local radiotherapy.
Cai R; Liu Y; Sha H; Yu J; Fang Y; Zhou G; Shen B
Heliyon; 2023 Nov; 9(11):e21902. PubMed ID: 38027958
[TBL] [Abstract][Full Text] [Related]
18. Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma.
Zhang D; Liang J; Lv Y; Huang X; Guo W
Medicine (Baltimore); 2022 Dec; 101(52):e32459. PubMed ID: 36596035
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers.
de Mestier L; Danset JB; Neuzillet C; Rebours V; Cros J; Soufir N; Hammel P
Endocr Relat Cancer; 2016 Oct; 23(10):T57-67. PubMed ID: 27511924
[TBL] [Abstract][Full Text] [Related]
20. BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts.
Lucas AL; Frado LE; Hwang C; Kumar S; Khanna LG; Levinson EJ; Chabot JA; Chung WK; Frucht H
Cancer; 2014 Jul; 120(13):1960-7. PubMed ID: 24737347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
